Gateways to clinical trials: May 2003

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 4, 2003, Pages 317-340

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 F5; 2 G12; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 AMINOPYRIDINE; ADALIMUMAB; ADEFOVIR DIPIVOXIL; AE 941; ALTROPANE; AMINOLEVULINIC ACID; AMINOPTERIN; BEVACIZUMAB; BIRICODAR; BRASOFENSINE; BRYOSTATIN 1; CGP 69846A; CREATINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAGLUTRIL; EDATREXATE; ESOMEPRAZOLE; ETORICOXIB; EVEROLIMUS; EZETIMIBE; FINGOLIMOD; HEPARIN; ISIS 104838; ISIS 2503; LENALIDOMIDE; LEVOSIMENDAN; MIBEFRADIL; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NEW DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMALIZUMAB; PACLITAXEL; PRO 200; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REGADENOSON; TENECTEPLASE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; VARDENAFIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACROMEGALY; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ANGINA PECTORIS; ARTHRITIS; ARTICLE; ASTHMA; ATTENTION DEFICIT DISORDER; BACKACHE; CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; DEPRESSION; DRUG INDICATION; DRUG RESEARCH; DRUG SELECTIVITY; DYSPEPSIA; EPILEPSY; ESOPHAGITIS; FIBROMYALGIA; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GAUCHER DISEASE; GLAUCOMA; GOUT; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; MEDICAL LITERATURE; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PAIN; PARKINSON DISEASE; POSTHERPETIC NEURALGIA; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

CLINICAL TRIALS; HUMANS;

EID: 0037787930     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (143)

1. Nissenson, A.R., Swan, S.K., Lindberg, J.S. et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002, 40(1): 110.
2. Bamias, A. et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (RHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncoloy 2003 64(2): 102.
3. Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med 2002, 346(7): 469.
4. Turner, S.P. et al. Mibefradil accelerates angiographic coronary flow in the coronary slow flow phenomenon. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 209B.
5. Borer, J.S. Fox, K., Jaillon, P., Lerebours, G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107(6): 817.
6. Corren, J., Casale, T., Deniz, Y., Ashby, M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hopitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003, 111(1): 87.
7. Thadani, U., Smith, W., Nash, S. et al. The effect vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002, 40(11): 2006.
8. Granger, C.B. et al. Differential impact of antithrombotic treatments (enoxaparin and abciximab) combined with tenecteplase in the elderly with acute MI: Results from ASSENT-3. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 204B.
9. Follath, F., Cleland, J.G.F., Just, H. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002, 360(9328): 196.
10. Sheth, T., Parker, T., Block, A. et al Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002, 90(5): 496.
11. Morkin, E., Pennock, G., Spooner, P.H., Bahl, J.J., Underhill-Fox K., Goldman, S. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology 2002, 97(4): 218.
12. Dickstein, K., de Voogd, H., Miric, M. et al. Inhibition of both neutral endopeptidase and edothelin converting enzyme lowers pulmonary pressures in congestive heart failure. J Am Coll Cardiol 2003, 41 (6, Suppl. A): 266A.
13. Mitchell, G.F., Izzo, J.L. Jr., Lacourcìere, Y. et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002, 105(25): 2955.
14. Eriksson, B.I., Ogren, M., Eriksson, U.G. et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: Results from phase II studies. Thromb Res 2002, 105(5): 371.
15. Connell, T.L.O., Clemmons, D.R. IGF-I/IGF-BP3 combination improves insulin resistance by GH dependent and GH independent mechanisms. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst P1-277.
16. Quarles, L.D., Sherrard, D.J., Adler S. et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003, 14(3): 575.
17. Noji, Y., Higashikata, T., Inazu, A. et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163(1): 157.
18. Siriwardena, D., Khaw, P.T., King, A.J. et al. Human antitransforming growth factor beta2 monoclonal antibody - a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical study. Ophthalmology 2002, 109(3): 427.
19. Broadway, D.C., Migdal, C.S., Salmon, J., Franks, W.A., Barton, K., Khaw, P.T. Adjunctive anti-TGFβ2 human monoclonal antibody as a novel agent to prevent scarring following phacotrabeculectomy. Annu Meet Assoc Res Vision Ophthalmol (May 5-May 10, 2002, Fort Lauderdale) 2002, Abst 3331.
20. Emmanuel, A.V., Roy, A.J., Nicholls, T.J., Kamm, M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002, 16(7): 1347.
21. Tack, J., Masclee, A., Heading, R. et al. A phase II randomised multicentric double-blind placebo controlled parallel group pilot study with Z-338 in functional dyspepsia (FD) patients. Gut 2002, 51(Suppl. 3): Abst OP-G-143.
22. Vakil, N.B., Zuckerman, S., Levine, J.G. H. pylori infection and the severity of esophagitis and healing with lansoprazole and esomeprazole. Gut 2002, 51 (Suppl. 3): Abst OP-G-043.
23. Johnson, D.A., Vakil, N.B., Richter, J.E., Zuckerman, S., Levine, J.G., Skammer, W. Sustained heartburn resolution during the first 4 weeks of PPI therapy predicts subsequent healing in GERD patients with erosive esophagitis. Gut 2002, 51 (Suppl. 3): Abst TUE-G-307.
24. Vakil, N.B., Zuckerman, S., Levine, J.G. Nocturnal heartburn in patients with erosive esophagitis and its resolution with proton pump inhibitors. Gut 2002, 51 (Suppl. 3): Abst TUE-G-321.
25. Lauritsen, K., Junghard, O., Eklund, S., Wiklund, I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux oesophagitis. Gut 2002, 51 (Suppl. 3): Abst TUE-G-310.
26. Vieth, M.V., Leodolter, A., Kulig, M. et al. The effects of esomeprazole on the oesophageal epithelium. Gut 2002, 51 (Suppl. 3): Abst TUE-G-322.
27. Dohmen, W., Fuchs, W.A.M., Seelis, R.E.A. Gastro-esophageal reflux disease (GERD): An investigation of efficacy and patients' satisfaction of an 'on-demand' therapy - lansoprazole vs. esomeprazole. Gut 2002, 51 (Suppl. 3): Abst TUE-G-520.
28. Scholten, T., Hole, U., Gatz, G. Pantoprazole 40 mg showed a significantly faster relief of GERD-associated symptoms than esomeprazole 40 mg. Gut 2002, 51 (Suppl. 3): Abst TUE-G-319.
29. Eissele, R., Gatz, G., Hole, U. Pantoprazole 40 mg and esomeprazole 40 mg show equivalent healing rates in patients with GERD. Gut 2002, 51 (Suppl. 3): Abst TUE-G-305.
30. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003, 348(9): 800.
31. Nishiguchi, S. et al. Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-α or -β therapy and effect of cisapride. Dig Dis Sci 2002, 47(1): 73.
32. Sulkowski, M. et al. Peginteferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: A phase II open-label study. Biodrugs 2002, 16(2): 105.
33. Heitner, R., Elstein, D., Aerts, J., van Weely, S., Zimran, A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type 1 Gaucher disease. Blood Cells Mol Dis 2002, 28(2): 127.
34. Rowbotham, M.C., Manville, N., Moreno-Lane, M., Ren, J. Prospective pilot study of levetiracetam for post-herpetic neuralgia pain and allodynia. Neurology 2003, 60 (5, Suppl. 1): Abst S62.004.
35. Geba, G., Bohidar, N., Straus, W., Petruschke, R. MOS SF-12 Short Form Health Survey evaluation of treatment outcomes with etoricoxib in patients with chronic low back pain. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 664.
36. Dissanayak, S., Royal, M., Wallace, M. Incidence of adverse events in patients on long-term (at least 6 months) ziconotide. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003. Chicago) 2003: Abst 886.
37. Dissanayake, S., Royal, M., Wallace, M. Relationship between intrathecal catheter tip level and neurological adverse events in patients receiving intrathecal ziconotide. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 885.
38. Ellis, D., Henderson, R., Royal, M., Slezak, J. Efficacy of intrathecal ziconotide in patients with chronic, severe pain. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 812.
39. Desai, A.A., Samra, S.S., Jagtap, S.A., Shah, R., Ram, S., Ballary, C. Assessment of the efficacy, safety & tolerability of parenteral parecoxib in adult patients of post-operative pain. Rheumatology (Oxford) 2003, 42 (Suppl. 1): Abst 267.
40. Mayer, K.H., Karim, S.A., Kelley, C. et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003, 17(3): 321.
41. van Zanten, S.J.O.V., Husein-Bhabha, F.A., Lee, J.S.M. Effectiveness of either esomeprazole or omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori (Hp) infection. Gut 2002, 51 (Suppl. 3): Abst MON-G-413.
42. Furusu, H., Isomoto, H., Kubo, K. et al. Lafutidine-based triple therapy for H. Pylori. Gut 2002, 51 (Suppl. 3): Abst MON-G-409.
43. Armbruster, C., Stiegler, G.M., Vcelar, B.A. et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002, 16(2): 227.
44. Walmsley, S. et al. Lopinavir-ritonavir versus nelfinavir for the initial treament of HIV infection. New Engl J Med 2002, 346(26): 2039.
45. Lindenburg, C.E.A. et al. Long-term follow-up: No effect of therapeutic vaccination with HIV-1 p17/p24: Ty virus-like particles on HIV-1 disease progression. Vaccine 2002, 20(17-18): 2343.
46. Murphy, R. et al. Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 Wk results from BMS A1424-044. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst LBPEB9013.
47. Evans, H., Milburn, M.L., Calloway, T., Volles, D.F., Lowson, S.M., Sawyer, R.G. Treating medical and surgical patients with activated protein C: A preliminary comparison. Critical Care (London) 2003, 7 (Suppl. 2): Abst P022.
48. Ozturk, Z., Woll, S., Najarian, D. et al. Comparison of indomethacin and etoricoxib, a new cyclo-oxygenase-2 inhibitor in acute gout. 22nd Annu Sci Meet Am Pain Sac (March 20, 2003, Chicago) 2003: Abst 653.
49. Clemmons, D.R., Sleevi, M., Busby, W.K. Recombinant human IGFBP-3 is preferentially degraded in humans in vivo and administration of RH IGFBP-3 to diabetics results in an increase in the concentration of glycosylated human IGFBP-3 in serum. 84th Annu Meet Endocr Soc (Jun 19-Jun 22, 2002, San Francisco) 2002. Abst P3-554.
50. Gegick, C.G., Altheimer, M.D. Thiazolidinediones (TZD): Comparison of long-term effects on lipids. Diabetes 2002, 51 (Suppl. 2): Abst 1737-P.
51. Kerzner, B., Corbelli, J., Sharp, S. et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003, 91(4): 418.
52. Geba, G.P., Birbara, C., Seger, W., Bohidar, N.R., Straus, W.L., Petruschke, R.A. Assessment of functional improvement in chronic low back pain patients with etoricoxib using the Roland-Morris disability questionnaire. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 1070.
53. Rowbotham, M., Crawford, L., Dworkin, R., Martin, S., Young, J., Knapp, L. Pregabalin improves pain associated with fibromyalgia syndrome (FMS) in a multicenter, randomized, placebo-controlled, monotherapy trial. Neurology 2003, 60 (5, Suppl, 1): Abst S62, 005.
54. Boonen, S. et al. Musculoskeletal effects of the recombinant human 1GF1/1GF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: A double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002, 87(4): 1593.
55. Alarcón-Segovia, D., Tumlin, J.A., Furie, R.A. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003, 48(2): 442.
56. Strand, V., Aranow, C., Cardiel, M. et al. Improvement in health-related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 221.
57. Petri, M., Ramsey-Goldman, R., Manzi, S. et al. Lupus disease activity and bone mineral density in women with active lupus: Results of a double-blind, multicenter trial comparing prasterone with placebo. Rheumatology (Oxford) 2003, 42 (Suppl, 1): Abst OP56.
58. Zanchetta, J.R. et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18(3): 539.
59. Eisen, G., Agrawal, N., Kent, J.D., Recker, D.P. Valdecoxib has a G1 safety and tolerability, profile superior to nonselective NSAIDs and similar to placebo in arthritis patients under 55 years. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 334.
60. Weinblatt, M.E., Keystone, E.C., Furst, D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48(1): 35.
61. Caldwell, J.R., Offenberg, H., Furst, D. et al. A phase 1 safety study of combination treatment with pegylated soluble tumor necrosis factor receptor type 1 (PET STNF-R1) and anakinra (interleukin-1 receptor antagonist, IL-IRA) in patients with rheumatoid arthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0087.
62. Rooney, T., Madigan, A., Dayer, J.-M. et al. Combination therapy with anakinra and PEGylated soluble tumor necrosis factor receptor type 1 in rheumatoid arthritis. A study of early clinical and synovial tissue responses. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 258.
63. Shergy, W.J., Cohen, S., Greenwald, M. et al. Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. 66th Annu Meet Am Coll Rheumatol (Oct 25. 2002, New Orleans) 2002: Abst LB 10.
64. Fleischmann, R., Tesser, J., Schechtman, J., Sun, G. Safety of anakinra (Interleukin-1 receptor antagonist) in rheumatoid arthritis (RA) subjects with potential high risk for infection. 66th Annu Meet Am Coll Rheumatol (Oct 25. 2002, New Orleans) 2002: Abst 870.
65. Choy, E.H.S., Isenberg, D.A., Garrood, T. et al. Blocking interleukin-6 (IL-6) by an anti-interleukin-6 receptor (IL-6R) monoclonal antibody in rheumatoid arthritis (RA). Rheumatology (Oxford) 2002, 41 (Suppl. 2): Abst OP43.
66. Moreland, L.W., Alten, R., Van den Bosch, F. et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46(6): 1470.
67. Guler, H.P., Caldwell, J.R., Fleischman, R.M. et al. Weekly treatment with IL-1 Trap is well tolerated and improves ACR criteria in patients with active rheumatoid arthritis. Eur Leag Against Rheum Congr (June 12. 2002, Stockholm) 2002: Abst OP0090.
68. Sewell, K.L., Geary, R.S., Baker, B.F. et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther 2002. 303(3): 1334.
69. Andrias, R., Porras, O., Rudge, S. et al. Preliminary data from a study of Kineret™ (anakinra) in children with juvenile rheumatoid arthritis. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 496.
70. Pillemer, S.R., Brennan, M., Sankar, V. et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren's syndrome. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 954.
71. Ibrahim, N.K., Desai, N., Legha, S. et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8(5): 1038.
72. Mani, S. et al. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002, 8(4): 1042.
73. Tolcher, A.W., Ochoa, L., Hammond, L.A. et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003, 21(2): 211.
74. Hovstadius, P., Larsson, R., Jonsson, E. et al. A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002, 8(9): 2843.
75. Wood, S., Schwartz, G., Garrison, M.A. et al. A phase 1, dose-escalating trial of ZD9331 in combination with docetaxel in patients with refractory solid malignancies. Proc Am Soc Clin Oncol 2002. 21 (Part 2): Abst 1843.
76. Kuriakose, P., Gandara, D.R., Perez, E.A. Phase 1 trial of edatrexate in advanced breast and other cancers. Cancer Invest 2002, 20(4): 473.
77. Adjei, A.A., Dy, G.K., Erlichman, C. et al. A phase 1 trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003, 9(1): 115.
78. Lockhart, A.C., Braun, R.D., Yu, D.H. et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003, 9(2): 586.
79. Awada, A., Giacchetti, S., Gerard, B. et al. Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: Report on three infusion schedules. Ann Oncol 2002, 13(12): 1925.
80. Rodriguez, G.I., Jones, R.E., Orenberg, E.K., Stoltz, M.L., Brooks, D.J. Phase I clinical trials of tezacitabine [(E)-2′-deoxy2′-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin Cancer Res 2002, 8(9): 2828.
81. Van Kesteren, C. et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anti-Cancer Drugs 2002, 13(4): 381.
82. Singletary, S.E., Atkinson, E.N., Hoque, A. et al. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002, 8(9): 2835.
83. Marriott, J.B., Clarke, I.A., Dredge, K., Muller, G., Stirling, D., Dalgleish, A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol 2003, 130(1): 75.
84. de Jong, A., O'Neill, T., Khan, A.Y. et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002, 20(29-30): 3456.
85. Schoffski, P., Herr, A., Vermorken, J.B. et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002, 38(6): 807.
86. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leacovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1): 60.
87. Louvet, C., Andre, T., Gamelin, E., Garcia, M.-L., Lenaers, G., Kalla, S. A phase I/II intra-patient dose escalating trial of ZD9331 in combination with irinotecan (CPT11) as second-line treatment for patients (pts) with metastatic cotorectal cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 2288.
88. Cripps, M.C., Figueredo, A.T., Oza, A.M. et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002, 8(7): 2188.
89. Miller, D.S., Herzog, T.J., Gordon, A.N. et al. A phase II trial of aminopterin in patients with advanced, persistent, or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 2002, 21 (Part I): Abst 866.
90. Antonia, S.J. et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002, 167(5): 1995.
91. Ritch, P., Belt, R., George, S. et al. Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1233.
92. Seiden, M.V., Swenerton, K.D., Matulonis, U. et al. A phase II/study of the MDR inhibitor biricodar (Incel, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002, 86(3): 302.
93. Smith, D.B., Gallagher, N., Garnett, S. A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 574.
94. Marriott, J.B., Clarke, I.A., Dredge, K. et al. Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation. Br J Cancer 2002, 86 (Suppl. I): Abst 6.4.
95. George, S., Maki, R.G., Harmon, D. et al. Phase II study of ecteinascidin-743 (ET-743) given by 3-hour IV infusion in patients (prs) with soft tissue sarcomas (STS) failing prior chemotherapies. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1630.
96. Fehr, M.K., Hornung, R., Desen, A. et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002, 30(4): 273.
97. Villaret, D., Glisson, B., Kenady, D. et al. A multicenter phase II study of tgDCC-EIA for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002, 24(7): 661.
98. Haas, N.B., Smith, M., Lewis, N. et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: A phase II study. Clin Cancer Res 2003, 9(1): 109.
99. Richardson, P.G., Schlossman, R.L., Weller, E. et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100(9): 3063.
100. Batist, G., Patenaude, F., Champagne, P. et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 2002, 13(8): 1259.
101. Szeimies, R.M., Karrer, S., Radakovic-Fijan, S. et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002, 47(2): 258.
102. Lancet, J.E., Rosenblatt, J.D., Karp, J.E. Farnesyltranaferase inhibitors and myelaid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias. Semin Hematol 2002. 39 (3, Suppl. 2): 31.
103. Loske, K.D., Gansz, B., Luger, T.A., Grabbe, S., Nashan, D. Pegylated interferon α-2b in the treatment of melanoma. Ann Dermatol Venereol 2002, 129 (1, Book 1): Abst IC0858.
104. Van den Berg, L.H., Groeneveld, G.J., Veldink, J.H. et al. A randomized placebo-controlled trial of creatiae in amyotrophic lateral sclerosis. Neurology 2003, 60 (5, Suppl. I): Abst S07.003.
105. Sachdeo, R.C., Montouris, G.D., Beydoun, A. et al. An open label, dose titration trial to evaluate tolerabitity and efficacy of oral SPM 927 as adjunctive therapy in patients with partial seizures. Neurology 2003, 60 (5, Suppl. 1): Abst S54.007.
106. Rey, E., Chjron, C., Tonnelier, S. et al. Stiripentol (STP) in childhood partial epilepsy: A randomized placebo-controlled trial with an enrichment and withdrawal design. Clin Pharmacol Ther 2003, 73(2): Abst PII-56.
107. Goodman, A.D., Blight, A., Cohen, J.A. et al. Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis. Neurology 2003, 60 (5, Suppl. 1): Abst S21.001.
108. Fischman, A.J., Bonab, A.A., Meltzer, P.C., Barrow, S.A., Madras, B.K. Evaluation of dopamine transporter (DAT) density in patients with Parkinson's disease (PD) by PET with 1271, IIC Altropane. J Nucl Med 2002, 43 (5, Suppl.): Abst No. 952.
109. Frackiewicz, E.J. et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother 2002, 36(2): 225.
110. Bara-Jimenez, W., Sherzai, A., Bibbiani, F. et al. 5-HT1A agonist effects in advanced Parkinson's disease. Neurology 2003, 60 (5, Suppl. 1): Abst S59.003.
111. Lyden, P. Pilot study of tenecteplase (TNK) in acute ischemic stroke: Preliminary report. Stroke 2003, 34(1): Abst 47.
112. Michelson, D., Adler, L., Spencer, T. et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53(2): 112.
113. Wohlreich, M., Mallinckrodt, C., Lu, Y., Detke, M. Treatment efficacy of daloxetine 60 mg QD for patients with major depression with painful physical symptoms. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 933.
114. Spasovski, G., Sikole, A., Gelev, S. et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients. Int J Artif Organs 2002, 25(7): Abst 39.
115. Sack, M. Fosrenol™ (lanthanum carbonate) is well tolerated in patients requiring hemodialysis: Results of a phase I clinical trial. J Am Soc Nephrol 2002. 13 (Abstracts issue): Abst SA-P0602.
116. Joy, M.S., Finn, W.F. Fosrenol™, a novel non-calcium, non-aluminium phosphate binder, has a good safety and efficacy profile in the long-term treatment of hyperphosphatemia in hemodialysis patients. J Am Soc Nephrol 2002, 13 (Abstracts issue): Abst SAP0-600.
117. De Broe, M.E. Fosrenol™ (lanthanum carbonate) vs. calcium carbonate for the treatment of hyperphosphataemia: A comparison of the effects on bone using biopsy examination. J Am Soc Nephrol 2002, 13 (Abstracts issue): Abst PUB487.
118. Hutchison, A.J. The novel, non-aluminium, non-calcium phosphate binder, Fosrenol™, is an affective treatment for hyperphosphataemia and has a good safety profile. J Am Soc Nephrol 2002, 13 (Abstracts issue): Abst SA-P0599.
119. Ferguson, R.M., Mulgaonkar, S., Tedesco, H. et al. FTY720 with reduced-exposure Neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results. 19th Int Congr Transplant Soc (Aug 25, 2002, Miami) 2002: Abst 0049.
120. Tedesco-Silva, H., Rosso-Felipe, C., Lorber, M. et al. FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function. 19th Int Congr Transplant Soc (Aug 25, 2002, Miami) 2002: Abst 0050.
121. Ettenger, R., Hoyer, P.F., Lemire, J., Webb, N.J.A., Mayer, H. Six-month results in pediatric de novo renal transplant patients treated with everolimus in combination with cyclosporine: Excellent efficacy in prevention of acute rejection and no occurrence of graft loss or death. 19th Int Congr Transplant Soc (Aug 25, 2002, Miami) 2002: Abst 0649.
122. Tedesco, H., Ambühl, P., Lorber, M., Oeyen, O., Pirron, U. Cyclosporine dose reduction in kidney transplant recipients taking everolimus (Certican™) improves renal function. 19th Int Congr Transplant Soc (Aug 25, 2002, Miami) 2002: Abst 0258.
123. Nickel, P., Bold, G., Bitti, D. et al. The cyclosporine dose influences the effects of FTY720-treatment on HCMV-specific T-cell memory response in renal allograft recipients. Am J Transplant 2002, 2 (Suppl. 3): Abst 192.
124. Griffiths, C.E.M., van Leent, E.J.M., Gilbert, M., Traulsen, J. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002, 147 (2): 299.
125. Sauder, D.N., Dekoven, J., Champagne, P., Croteau, D., Dupont, E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002, 47(4): 535.
126. Ellis, C.N., Mordin, M.M., Adler, E.Y. Effects of alefacept on health-related quality of life in patients with psoriasis: Results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003, 4(2): 131.
127. Papp, K.A., Miller, B., Lynde, C., Leonardi, C.L. Efalizumab (anti-CD11a) retreatment: Final results from an open-label study in psoriasis. 61st Annu Meet Am Acad Dermatol (March 21, 2003, San Francisco) 2003: Abst P614.
128. Feldman, S.R., Siegfried, E.C., Langley, R., Koo, J.Y. Effects of efalizumab (anti-CD11a) on patient-reported outcomes in subjects with moderate to severe plaque psoriasis. 61st Annu Meet Am Acad Dermatol (March 21, 2003, San Francisco) 2003: Abst P588.
129. Hamilton, T., Powers, J., Carey, W., Menter, A. Efficacy and safety of efalizumab (anti-CD11a) in subjects with moderate to severe plaque psoriasis. 61st Annu Meet Am Acad Dermatol (March 21, 2003, San Francisco) 2003: Abst P602.
130. Gottlieb, A.B., Blacker, K., Duvic, M., Leonardi, C.L. Efficacy and safety of efalizumab (anti-CD11a) long-term treatment: Preliminary findings from an open-label trial. 61st Annu Meet Am Acad Dermatol (March 21, 2003, San Francisco) 2003: Abst P11.
131. Kimball, A.B., Kawamura, T., Tejura, K. et al. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 2002, 138(10): 1341.
132. Casati, A. et al. Clinical properties of levobupivacaine or racemic bupivacaine for sciatic nerve block. J Clin Anesth 2002, 14(2): 111.
133. El-Orbany, M.I. et al. Tracheal intubation conditions and cardiovascular effects after modified rapid-sequence induction with sevoflurane-rapacuronium versus propofol-rapacuronium. J Clin Anesth 2002, 14(2): 115.
134. Skarke, C., Darimont, J., Schmidt, H., Geisslinger, G. Lötsch, Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneons electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003, 73(1): 107.
135. Cannon, R.O., Freestone, S., Mair, S.J. et al. A randomized, placebo-controlled, crossover, ascending dose tolerance and pharmacokinetic study of CVT-3146: A novel agent for potential use in myocardial perfusion imaging. Clin Pharmacol Ther 2003, 73(2): Abst PII-8.
136. Howes, J.F., Verhangen, A., Halabi, A., Bodor, N. Etiprednol dicloacetate, a corticosteroid with no effects on HPA axis function: A randomized controlled assessment in healthy volunteers. Clin Pharmacol Ther 2003, 73(2): Abst PII-94.
137. Stewart, I. Administration of a novel phosphate binder, Fosrenol™, with food is associated with good tolerability and low systemic absorption. J Am Soc Nephrol 2002, 13 (Abstracts issue): Abst SA-P0601.
138. Stewart, A.J. Fosrenol™ - a novel non-calcium, non-aluminium phosphate binder - is well tolerated when given during or after food intake. J Am Soc Nephrol 2002, 13 (Abstracts issue): Abst PUB397.
139. Griffin, N., Zimmerman, D.D.E., Briel, J.W. et al. Topical L-arginine gel lowers resting and pressure: Possible treatment for anal fissure. Dis Colon Rectum 2002, 45(10): 1332.
140. Van der Zander, K., Houben, A.J.H.M., Hofstra, L., Kroon, A.A., de Leeuw, P.W. Central and peripheral hemodynamic effects of brain natriuretic peptide infusion in man. J Hypertens 2002, 20 (Suppl. 4): Abst P0918.
141. Beckman, J.A., Goldfine, A.B., Gordon, M.B., Garrett, L.A., Creager, M.A. Inhibition of protein kinase cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002, 90(1): 107.
142. Fijen, J.W., Tulleken, J.E., Kobold, A.C. et al. Inhibition of p38 mitogen-activated protein kinase: Dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 2002, 30(4): 841.
143. Seed, A., Kuc, R., Davenport, A. et al. First demonstration in humans of sytemic neutral endopeptidase and endothelin converting enzyme inhibition using a new orally active dual metalloprotease inhibitor SLV 306. J Am Coll Cardiol 2003, 41(6, Suppl. A): 265A.